25 XP   0   0   10

Atara Biotherapeutics Inc
Buy, Hold or Sell?

Let's analyse Atara Biotherapeutics Inc together

PenkeI guess you are interested in Atara Biotherapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Atara Biotherapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Atara Biotherapeutics Inc

I send you an email if I find something interesting about Atara Biotherapeutics Inc.

Quick analysis of Atara Biotherapeutics Inc (30 sec.)










What can you expect buying and holding a share of Atara Biotherapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
7.5%

What is your share worth?

Current worth
$-0.92
Expected worth in 1 year
$-3.06
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-2.14
Return On Investment
-324.4%

For what price can you sell your share?

Current Price per Share
$0.66
Expected price per share
$0.4323 - $0.9375
How sure are you?
50%

1. Valuation of Atara Biotherapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$0.66

Intrinsic Value Per Share

$-36.58 - $-20.63

Total Value Per Share

$-37.50 - $-21.55

2. Growth of Atara Biotherapeutics Inc (5 min.)




Is Atara Biotherapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$99.2m$198.8m-$218.3m-1,124.5%

How much money is Atara Biotherapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$69m-$57m-$11.9m-17.4%
Net Profit Margin-4,553.8%-9,199.0%--

How much money comes from the company's main activities?

3. Financial Health of Atara Biotherapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#998 / 1016

Most Revenue
#440 / 1016

Most Profit
#932 / 1016

Most Efficient
#905 / 1016

What can you expect buying and holding a share of Atara Biotherapeutics Inc? (5 min.)

Welcome investor! Atara Biotherapeutics Inc's management wants to use your money to grow the business. In return you get a share of Atara Biotherapeutics Inc.

What can you expect buying and holding a share of Atara Biotherapeutics Inc?

First you should know what it really means to hold a share of Atara Biotherapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Atara Biotherapeutics Inc is $0.661. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Atara Biotherapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Atara Biotherapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.92. Based on the TTM, the Book Value Change Per Share is $-0.54 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.38 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Atara Biotherapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.56-84.6%-0.65-98.7%-0.56-84.2%-0.70-106.2%-0.48-72.8%
Usd Book Value Change Per Share-0.44-66.5%-0.54-81.1%-0.38-57.3%-0.21-32.1%-0.02-3.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.44-66.5%-0.54-81.1%-0.38-57.3%-0.21-32.1%-0.02-3.1%
Usd Price Per Share0.51-1.63-6.04-12.02-17.94-
Price to Earnings Ratio-0.23--0.60-1.44--3.33--15.70-
Price-to-Total Gains Ratio-1.17--2.90--1.02--19.95--41.49-
Price to Book Ratio-0.56-5.92-3.01-5.23-7.77-
Price-to-Total Gains Ratio-1.17--2.90--1.02--19.95--41.49-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.661
Number of shares1512
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.54-0.21
Usd Total Gains Per Share-0.54-0.21
Gains per Quarter (1512 shares)-810.49-320.62
Gains per Year (1512 shares)-3,241.95-1,282.48
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11-3243-32520-1283-1292
23-6487-64941-2566-2574
34-9730-97361-3849-3856
45-12973-129782-5132-5138
57-16217-162202-6414-6420
68-19460-194622-7697-7702
710-22703-227043-8980-8984
811-25947-259463-10263-10266
912-29190-291884-11546-11548
1014-32433-324304-12829-12830

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%1.040.00.02.4%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%10.030.00.025.0%10.031.00.024.4%
Dividend per Share2.00.02.050.0%3.00.09.025.0%3.00.017.015.0%3.00.037.07.5%3.00.038.07.3%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%10.030.00.025.0%10.031.00.024.4%

Fundamentals of Atara Biotherapeutics Inc

About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Fundamental data was last updated by Penke on 2024-04-11 01:23:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Atara Biotherapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Atara Biotherapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -1,421.7% means that $-14.22 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Atara Biotherapeutics Inc:

  • The MRQ is -1,421.7%. The company is making a huge loss. -2
  • The TTM is -4,553.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,421.7%TTM-4,553.8%+3,132.2%
TTM-4,553.8%YOY-9,199.0%+4,645.2%
TTM-4,553.8%5Y-3,109.8%-1,444.1%
5Y-3,109.8%10Y-1,554.9%-1,554.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,421.7%-199.6%-1,222.1%
TTM-4,553.8%-213.0%-4,340.8%
YOY-9,199.0%-279.3%-8,919.7%
5Y-3,109.8%-438.4%-2,671.4%
10Y-1,554.9%-605.5%-949.4%
1.1.2. Return on Assets

Shows how efficient Atara Biotherapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • -36.5% Return on Assets means that Atara Biotherapeutics Inc generated $-0.37 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Atara Biotherapeutics Inc:

  • The MRQ is -36.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -31.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-36.5%TTM-31.8%-4.7%
TTM-31.8%YOY-15.1%-16.6%
TTM-31.8%5Y-21.2%-10.6%
5Y-21.2%10Y-15.5%-5.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-36.5%-13.5%-23.0%
TTM-31.8%-12.9%-18.9%
YOY-15.1%-11.8%-3.3%
5Y-21.2%-14.1%-7.1%
10Y-15.5%-16.0%+0.5%
1.1.3. Return on Equity

Shows how efficient Atara Biotherapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Atara Biotherapeutics Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-267.3%+267.3%
TTM-267.3%YOY-34.0%-233.3%
TTM-267.3%5Y-75.2%-192.1%
5Y-75.2%10Y-42.3%-32.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM-267.3%-16.1%-251.2%
YOY-34.0%-15.1%-18.9%
5Y-75.2%-19.9%-55.3%
10Y-42.3%-20.9%-21.4%

1.2. Operating Efficiency of Atara Biotherapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Atara Biotherapeutics Inc is operating .

  • Measures how much profit Atara Biotherapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -1,253.0% means the company generated $-12.53  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Atara Biotherapeutics Inc:

  • The MRQ is -1,253.0%. The company is operating very inefficient. -2
  • The TTM is -4,489.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,253.0%TTM-4,489.3%+3,236.4%
TTM-4,489.3%YOY-9,478.7%+4,989.3%
TTM-4,489.3%5Y-3,154.8%-1,334.6%
5Y-3,154.8%10Y-1,577.4%-1,577.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,253.0%-295.1%-957.9%
TTM-4,489.3%-225.8%-4,263.5%
YOY-9,478.7%-288.4%-9,190.3%
5Y-3,154.8%-477.4%-2,677.4%
10Y-1,577.4%-625.6%-951.8%
1.2.2. Operating Ratio

Measures how efficient Atara Biotherapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 13.53 means that the operating costs are $13.53 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 13.530. The company is inefficient in keeping operating costs low. -1
  • The TTM is 46.225. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ13.530TTM46.225-32.695
TTM46.225YOY99.220-52.995
TTM46.2255Y32.884+13.341
5Y32.88410Y16.442+16.442
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.5303.090+10.440
TTM46.2253.264+42.961
YOY99.2203.783+95.437
5Y32.8845.679+27.205
10Y16.4427.894+8.548

1.3. Liquidity of Atara Biotherapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.72 means the company has $0.72 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.716. The company is unable to pay all its short-term debts. -2
  • The TTM is 1.958. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ0.716TTM1.958-1.242
TTM1.958YOY4.009-2.051
TTM1.9585Y5.540-3.582
5Y5.54010Y15.176-9.636
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7163.914-3.198
TTM1.9584.220-2.262
YOY4.0095.388-1.379
5Y5.5406.045-0.505
10Y15.1766.406+8.770
1.3.2. Quick Ratio

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.79 means the company can pay off $0.79 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.787. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 2.853. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.787TTM2.853-2.067
TTM2.853YOY6.476-3.623
TTM2.8535Y8.982-6.129
5Y8.98210Y25.694-16.712
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7873.572-2.785
TTM2.8533.998-1.145
YOY6.4765.390+1.086
5Y8.9825.969+3.013
10Y25.6946.287+19.407

1.4. Solvency of Atara Biotherapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Atara Biotherapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Atara Biotherapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.60 means that Atara Biotherapeutics Inc assets are financed with 160.0% credit (debt) and the remaining percentage (100% - 160.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 1.600. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.156. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.600TTM1.156+0.444
TTM1.156YOY0.500+0.656
TTM1.1565Y0.451+0.705
5Y0.45110Y0.321+0.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6000.336+1.264
TTM1.1560.334+0.822
YOY0.5000.269+0.231
5Y0.4510.366+0.085
10Y0.3210.390-0.069
1.4.2. Debt to Equity Ratio

Measures if Atara Biotherapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM8.928-8.928
TTM8.928YOY1.101+7.826
TTM8.9285Y2.166+6.762
5Y2.16610Y1.115+1.051
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM8.9280.396+8.532
YOY1.1010.335+0.766
5Y2.1660.434+1.732
10Y1.1150.465+0.650

2. Market Valuation of Atara Biotherapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Atara Biotherapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.23 means the investor is paying $-0.23 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is -0.296. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.229. Based on the earnings, the company is expensive. -2
  • The TTM is -0.599. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.296MRQ-0.229-0.066
MRQ-0.229TTM-0.599+0.370
TTM-0.599YOY1.444-2.043
TTM-0.5995Y-3.329+2.730
5Y-3.32910Y-15.705+12.376
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.296-2.259+1.963
MRQ-0.229-2.569+2.340
TTM-0.599-2.664+2.065
YOY1.444-4.120+5.564
5Y-3.329-6.258+2.929
10Y-15.705-6.171-9.534
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is -0.354. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.275. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.943. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.354MRQ-0.275-0.079
MRQ-0.275TTM-0.943+0.668
TTM-0.943YOY-2.181+1.238
TTM-0.9435Y-10.050+9.107
5Y-10.05010Y-27.711+17.662
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.354-2.924+2.570
MRQ-0.275-3.246+2.971
TTM-0.943-3.488+2.545
YOY-2.181-5.620+3.439
5Y-10.050-8.315-1.735
10Y-27.711-8.826-18.885
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Atara Biotherapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.56 means the investor is paying $-0.56 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is -0.720. Based on the equity, the company is expensive. -2
  • The MRQ is -0.559. Based on the equity, the company is expensive. -2
  • The TTM is 5.921. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD-0.720MRQ-0.559-0.161
MRQ-0.559TTM5.921-6.480
TTM5.921YOY3.012+2.909
TTM5.9215Y5.229+0.692
5Y5.22910Y7.774-2.546
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.7201.851-2.571
MRQ-0.5592.090-2.649
TTM5.9212.095+3.826
YOY3.0122.844+0.168
5Y5.2293.466+1.763
10Y7.7743.815+3.959
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Atara Biotherapeutics Inc.

3.1. Institutions holding Atara Biotherapeutics Inc

Institutions are holding 73.735% of the shares of Atara Biotherapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31EcoR1 Capital, LLC9.87720.13410067043100670430
2023-12-31BlackRock Inc6.95350.00017087213-608722-7.9097
2023-12-31Vanguard Group Inc6.55990.00016686043801101.2127
2023-09-30Redmile Group, LLC6.16240.442362808132326903.8473
2023-09-30D. E. Shaw & Co LP3.83670.0063910416-438912-10.0915
2023-12-31UBS Group AG3.62360.0006369322536347336214.0686
2023-12-31AQR Capital Management LLC2.8770.002829323102087858247.2441
2023-12-31Millennium Management LLC2.86590.000729209802593916793.0913
2023-12-31State Street Corporation2.73170.0001278420026151410.3665
2023-12-31JPMorgan Chase & Co2.14680.00012188044-6479550-74.756
2023-12-31Geode Capital Management, LLC2.10960.00012150150735753.5431
2023-12-31Morgan Stanley - Brokerage Accounts1.75950.00011793371-421314-19.0237
2023-12-31Acadian Asset Management LLC1.73230.003517655541231161230.3849
2023-09-30Citadel Advisors Llc1.63960.0005167114553786247.4605
2023-12-31Goldman Sachs Group Inc1.14240.00011164378-2960031-71.7686
2023-09-30Antipodean Advisors LLC0.98117.5826100000000
2023-12-31Staley Capital Advisers Inc0.98110.0255100000000
2023-12-31Northern Trust Corp0.82950.0001845427465055.821
2023-12-31GSA Capital Partners LLP0.76960.03387843677843670
2023-12-31Charles Schwab Investment Management Inc0.73110.0001745145-48412-6.1006
Total 60.31058.233261469824+10674393+17.4%

3.2. Funds holding Atara Biotherapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.27070.0001271023600
2024-03-28iShares Russell 2000 ETF2.01250.0026240210511580.0482
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.12310.001134052300
2023-12-31Vanguard Explorer Inv0.93240.0027111288200
2024-01-31Fidelity Small Cap Index0.81610.0025974144193332.0248
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.80220.0018957477253002.7141
2024-03-28iShares Russell 2000 Value ETF0.70630.0047842975-535-0.0634
2024-02-29JPMorgan US Small Company L0.4280.040551082800
2024-03-29Schwab US Small-Cap ETF™0.4060.00248461700
2024-02-29Fidelity Extended Market Index0.37340.0009445678-120427-21.2729
2023-12-31Vanguard Strategic Small-Cap Equity Inv0.33880.0139404425-95822-19.1549
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.30240.002636098200
2024-02-29Vanguard Russell 2000 ETF0.29750.0029355044276698.4518
2024-02-29SPDR® Russell 2000 US Small Cap ETF0.2610.0091311479158115.3476
2024-02-29Vanguard Health Care ETF0.23210.00127703314880.54
2023-12-31NT R2000 Index Fund - NL0.22790.00192720473640.134
2023-12-31NT R2000 Value Index Fund - NL0.2140.003525547400
2024-01-31Fidelity VIP Disciplined Small Cap Init0.20170.040924077800
2024-02-29Schwab Small Cap Index0.19740.003123564500
2023-09-30BlackRock Extended Mkt Composite0.19050.002422743617110.758
Total 12.3340.140114721808-123950-0.8%

3.3. Insider Transactions

Insiders are holding 6.347% of the shares of Atara Biotherapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-04Anhco NguyenSELL107460.72
2024-03-04Pascal TouchonSELL248440.72
2023-11-16Anhco NguyenSELL88560.39
2023-11-16Eric J HyllengrenSELL119580.39
2023-11-16Pascal TouchonSELL204090.39
2023-11-13Carol Giltner GallagherBUY1790200.22
2023-11-10William K HeidenBUY1000000.25
2023-08-16Amar MuruganSELL86721.65
2023-08-16Eric J HyllengrenSELL81861.65
2023-08-16Pascal TouchonSELL307661.65
2023-06-27Pascal TouchonSELL142911.66
2023-05-16Amar MuruganSELL83892.04
2023-05-16Eric J HyllengrenSELL79182.04
2023-05-16Pascal TouchonSELL297662.04

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Atara Biotherapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.440-0.536+22%-0.379-14%-0.212-52%-0.020-95%
Book Value Per Share---0.918-0.175-81%1.945-147%2.265-141%2.280-140%
Current Ratio--0.7161.958-63%4.009-82%5.540-87%15.176-95%
Debt To Asset Ratio--1.6001.156+38%0.500+220%0.451+255%0.321+398%
Debt To Equity Ratio---8.928-100%1.101-100%2.166-100%1.115-100%
Dividend Per Share---0.000-100%0.000-100%0.000-100%0.000-100%
Eps---0.559-0.653+17%-0.5570%-0.702+26%-0.481-14%
Free Cash Flow Per Share---0.467-0.458-2%-0.671+44%-0.549+18%-0.382-18%
Free Cash Flow To Equity Per Share---0.453-0.453+0%-0.542+20%-0.168-63%-0.019-96%
Gross Profit Margin--1.0181.004+1%1.000+2%1.001+2%1.000+2%
Intrinsic Value_10Y_max---20.634--------
Intrinsic Value_10Y_min---36.585--------
Intrinsic Value_1Y_max---1.609--------
Intrinsic Value_1Y_min---2.516--------
Intrinsic Value_3Y_max---5.185--------
Intrinsic Value_3Y_min---8.601--------
Intrinsic Value_5Y_max---9.182--------
Intrinsic Value_5Y_min---15.779--------
Market Cap67370442.000+18%55451628.000170907929.500-68%616602635.000-91%1226103321.900-95%1828726315.950-97%
Net Profit Margin---14.217-45.538+220%-91.990+547%-31.098+119%-15.549+9%
Operating Margin---12.530-44.893+258%-94.787+656%-31.548+152%-15.774+26%
Operating Ratio--13.53046.225-71%99.220-86%32.884-59%16.442-18%
Pb Ratio-0.720-29%-0.5595.921-109%3.012-119%5.229-111%7.774-107%
Pe Ratio-0.296-29%-0.229-0.599+161%1.444-116%-3.329+1352%-15.705+6748%
Price Per Share0.661+22%0.5131.626-68%6.035-92%12.017-96%17.936-97%
Price To Free Cash Flow Ratio-0.354-29%-0.275-0.943+243%-2.181+694%-10.050+3557%-27.711+9985%
Price To Total Gains Ratio-1.503-29%-1.166-2.897+149%-1.015-13%-19.948+1611%-41.494+3459%
Quick Ratio--0.7872.853-72%6.476-88%8.982-91%25.694-97%
Return On Assets---0.365-0.318-13%-0.151-59%-0.212-42%-0.155-58%
Return On Equity----2.6730%-0.3400%-0.7520%-0.4230%
Total Gains Per Share---0.440-0.536+22%-0.379-14%-0.212-52%-0.020-95%
Usd Book Value---99231000.000-19413750.000-80%198887000.000-150%230694000.000-143%232236450.000-143%
Usd Book Value Change Per Share---0.440-0.536+22%-0.379-14%-0.212-52%-0.020-95%
Usd Book Value Per Share---0.918-0.175-81%1.945-147%2.265-141%2.280-140%
Usd Dividend Per Share---0.000-100%0.000-100%0.000-100%0.000-100%
Usd Eps---0.559-0.653+17%-0.5570%-0.702+26%-0.481-14%
Usd Free Cash Flow---50450000.000-48550000.000-4%-68655750.000+36%-56327800.000+12%-39178800.000-22%
Usd Free Cash Flow Per Share---0.467-0.458-2%-0.671+44%-0.549+18%-0.382-18%
Usd Free Cash Flow To Equity Per Share---0.453-0.453+0%-0.542+20%-0.168-63%-0.019-96%
Usd Market Cap67370442.000+18%55451628.000170907929.500-68%616602635.000-91%1226103321.900-95%1828726315.950-97%
Usd Price Per Share0.661+22%0.5131.626-68%6.035-92%12.017-96%17.936-97%
Usd Profit---60450000.000-69031500.000+14%-57046750.000-6%-72102500.000+19%-48912900.000-19%
Usd Revenue--4252000.0002143250.000+98%15893250.000-73%4624300.000-8%2312150.000+84%
Usd Total Gains Per Share---0.440-0.536+22%-0.379-14%-0.212-52%-0.020-95%
 EOD+6 -2MRQTTM+18 -17YOY+13 -225Y+14 -2110Y+9 -26

4.2. Fundamental Score

Let's check the fundamental score of Atara Biotherapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.296
Price to Book Ratio (EOD)Between0-1-0.720
Net Profit Margin (MRQ)Greater than0-14.217
Operating Margin (MRQ)Greater than0-12.530
Quick Ratio (MRQ)Greater than10.787
Current Ratio (MRQ)Greater than10.716
Debt to Asset Ratio (MRQ)Less than11.600
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.365
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Atara Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.690
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Working Capital  216,164-59,858156,306-58,53897,768-58,16139,607-79,964-40,357



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets165,504
Total Liabilities264,735
Total Stockholder Equity-99,231
 As reported
Total Liabilities 264,735
Total Stockholder Equity+ -99,231
Total Assets = 165,504

Assets

Total Assets165,504
Total Current Assets101,869
Long-term Assets63,635
Total Current Assets
Cash And Cash Equivalents 25,987
Short-term Investments 25,884
Net Receivables 34,108
Inventory 9,706
Other Current Assets 6,184
Total Current Assets  (as reported)101,869
Total Current Assets  (calculated)101,869
+/-0
Long-term Assets
Property Plant Equipment 58,791
Long-term Assets Other 4,844
Long-term Assets  (as reported)63,635
Long-term Assets  (calculated)63,635
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities142,226
Long-term Liabilities122,509
Total Stockholder Equity-99,231
Total Current Liabilities
Short-term Debt 12,179
Accounts payable 3,684
Other Current Liabilities 48,530
Total Current Liabilities  (as reported)142,226
Total Current Liabilities  (calculated)64,393
+/- 77,833
Long-term Liabilities
Capital Lease Obligations 57,872
Long-term Liabilities Other 39,254
Long-term Liabilities  (as reported)122,509
Long-term Liabilities  (calculated)97,126
+/- 25,383
Total Stockholder Equity
Common Stock11
Retained Earnings -1,969,150
Accumulated Other Comprehensive Income -204
Other Stockholders Equity 1,870,112
Total Stockholder Equity (as reported)-99,231
Total Stockholder Equity (calculated)-99,231
+/-0
Other
Capital Stock11
Cash and Short Term Investments 51,871
Common Stock Shares Outstanding 108,135
Current Deferred Revenue77,833
Liabilities and Stockholders Equity 165,504
Net Debt 31,885
Net Invested Capital -99,231
Net Working Capital -40,357
Property Plant and Equipment Gross 74,660
Short Long Term Debt Total 57,872



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
4,290
0
0
0
51,828
62,866
58,503
54,120
106,122
169,817
161,102
340,379
324,975
312,978
300,814
284,417
263,914
241,738
244,155
229,693
217,779
473,108
492,707
442,940
391,839
324,726
274,144
364,785
342,942
299,547
428,111
405,532
588,120
529,637
456,791
449,923
468,127
397,280
436,121
368,316
376,420
302,083
246,439
188,788
165,504
165,504188,788246,439302,083376,420368,316436,121397,280468,127449,923456,791529,637588,120405,532428,111299,547342,942364,785274,144324,726391,839442,940492,707473,108217,779229,693244,155241,738263,914284,417300,814312,978324,975340,379161,102169,817106,12254,12058,50362,86651,8280004,290
   > Total Current Assets 
0
0
0
0
51,808
62,291
57,085
52,022
106,026
169,691
160,634
340,235
324,597
311,741
298,883
282,230
260,553
235,318
222,492
206,217
172,190
413,614
425,070
372,976
321,489
250,830
201,139
293,418
272,992
229,217
358,987
339,432
523,273
464,307
392,325
369,497
384,621
314,389
346,984
283,046
295,080
224,182
172,320
118,696
101,869
101,869118,696172,320224,182295,080283,046346,984314,389384,621369,497392,325464,307523,273339,432358,987229,217272,992293,418201,139250,830321,489372,976425,070413,614172,190206,217222,492235,318260,553282,230298,883311,741324,597340,235160,634169,691106,02652,02257,08562,29151,8080000
       Cash And Cash Equivalents 
4,207
0
0
0
51,615
39,754
31,779
25,703
21,897
71,329
26,190
54,466
23,746
22,056
26,356
46,013
47,968
62,430
64,237
60,493
79,223
90,495
103,203
66,028
60,698
56,168
59,159
94,431
74,317
70,203
74,511
62,620
200,404
151,097
123,856
113,209
106,084
101,669
70,688
65,114
92,942
48,741
45,898
64,791
25,987
25,98764,79145,89848,74192,94265,11470,688101,669106,084113,209123,856151,097200,40462,62074,51170,20374,31794,43159,15956,16860,69866,028103,20390,49579,22360,49364,23762,43047,96846,01326,35622,05623,74654,46626,19071,32921,89725,70331,77939,75451,6150004,207
       Short-term Investments 
0
0
0
0
0
22,277
24,719
25,996
82,219
95,367
128,841
279,799
296,736
284,347
268,201
232,134
207,714
168,216
152,659
139,728
86,873
316,826
313,812
298,515
248,933
181,377
130,976
188,491
184,792
144,428
273,201
264,565
300,255
284,064
249,524
244,036
264,984
200,142
260,623
200,290
149,877
156,666
107,744
37,617
25,884
25,88437,617107,744156,666149,877200,290260,623200,142264,984244,036249,524284,064300,255264,565273,201144,428184,792188,491130,976181,377248,933298,515313,812316,82686,873139,728152,659168,216207,714232,134268,201284,347296,736279,799128,84195,36782,21925,99624,71922,27700000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
800
800
1,250
9,610
700
400
986
668
637
249
40,221
397
507
163
34,108
34,10816350739740,2212496376689864007009,6101,250800800000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,586
5,340
7,861
6,591
9,706
9,7066,5917,8615,3401,5860000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
20
575
1,418
2,098
96
126
468
144
378
1,237
1,931
2,187
3,361
6,420
21,663
23,476
45,589
59,494
67,637
69,964
70,350
73,896
73,005
71,367
69,950
70,330
69,124
66,100
64,847
65,330
64,466
80,426
83,506
82,891
89,137
85,270
81,340
77,901
74,119
70,092
63,635
63,63570,09274,11977,90181,34085,27089,13782,89183,50680,42664,46665,33064,84766,10069,12470,33069,95071,36773,00573,89670,35069,96467,63759,49445,58923,47621,6636,4203,3612,1871,9311,237378144468126962,0981,418575200000
       Property Plant Equipment 
9
0
0
0
8
8
11
14
48
47
42
46
270
1,148
1,830
2,085
3,259
4,400
20,287
22,176
44,129
58,194
66,075
68,279
68,576
72,160
71,486
69,901
68,183
68,133
66,908
64,023
62,820
63,401
62,577
78,556
79,939
28,042
81,910
78,104
74,322
70,995
67,544
63,803
58,791
58,79163,80367,54470,99574,32278,10481,91028,04279,93978,55662,57763,40162,82064,02366,90868,13368,18369,90171,48672,16068,57668,27966,07558,19444,12922,17620,2874,4003,2592,0851,8301,148270464247481411880009
       Long-term Assets Other 
0
0
0
0
12
567
1,407
2,084
48
79
426
98
108
89
101
102
102
2,020
1,376
1,300
1,460
1,300
1,562
1,685
1,774
1,736
1,519
1,466
1,767
2,197
2,216
2,077
2,027
1,929
1,889
1,870
3,567
54,849
7,227
7,166
7,018
6,906
6,575
6,289
4,844
4,8446,2896,5756,9067,0187,1667,22754,8493,5671,8701,8891,9292,0272,0772,2162,1971,7671,4661,5191,7361,7741,6851,5621,3001,4601,3001,3762,020102102101891089842679482,0841,407567120000
> Total Liabilities 
1,306
0
0
0
62,845
77,570
2,280
77,149
2,940
3,723
11,847
6,631
9,875
9,144
10,569
14,215
10,178
8,604
23,011
23,737
39,915
33,924
40,208
39,886
52,982
40,792
41,865
46,343
52,161
46,725
46,986
51,597
125,781
130,600
125,253
139,782
188,513
172,964
178,642
181,203
249,780
237,123
238,985
239,626
264,735
264,735239,626238,985237,123249,780181,203178,642172,964188,513139,782125,253130,600125,78151,59746,98646,72552,16146,34341,86540,79252,98239,88640,20833,92439,91523,73723,0118,60410,17814,21510,5699,1449,8756,63111,8473,7232,94077,1492,28077,57062,8450001,306
   > Total Current Liabilities 
1,302
0
0
0
1,524
2,788
2,101
2,412
2,724
3,514
11,644
6,450
9,709
8,860
10,006
13,688
9,675
7,805
11,481
16,516
27,646
21,049
27,234
27,000
39,979
25,175
25,803
30,706
36,743
31,520
31,684
36,055
82,901
84,194
88,830
86,150
105,786
101,562
65,688
72,244
78,916
67,876
74,552
79,089
142,226
142,22679,08974,55267,87678,91672,24465,688101,562105,78686,15088,83084,19482,90136,05531,68431,52036,74330,70625,80325,17539,97927,00027,23421,04927,64616,51611,4817,8059,67513,68810,0068,8609,7096,45011,6443,5142,7242,4122,1012,7881,5240001,302
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
10,300
10,300
0
0
643
0
0
1,581
0
0
0
1,985
23,441
28,194
29,114
2,753
0
0
837
13,640
12,610
12,954
13,296
12,179
12,17913,29612,95412,61013,640837002,75329,11428,19423,4411,9850001,581006430010,30010,30050000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
10,300
10,300
0
0
643
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000006430010,30010,30050000000000000000000000
       Accounts payable 
121
0
0
0
606
1,402
577
569
440
794
1,703
1,853
1,445
1,896
3,235
4,463
2,778
2,204
5,243
5,539
14,711
6,098
6,545
6,193
3,719
6,168
6,420
5,155
7,963
8,079
5,106
5,190
7,118
17,355
12,301
16,543
17,368
11,945
12,799
11,296
6,871
5,068
4,138
6,511
3,684
3,6846,5114,1385,0686,87111,29612,79911,94517,36816,54312,30117,3557,1185,1905,1068,0797,9635,1556,4206,1683,7196,1936,5456,09814,7115,5395,2432,2042,7784,4633,2351,8961,4451,8531,7037944405695771,402606000121
       Other Current Liabilities 
1,174
0
0
0
918
1,386
1,524
1,843
2,284
2,720
9,941
4,597
8,264
6,964
6,771
9,225
6,897
5,601
6,238
10,977
12,935
14,951
20,689
20,807
36,260
19,007
19,383
25,551
5,733
23,441
26,578
30,865
40,343
7,901
7,367
9,267
44,905
38,674
51,218
57,449
50,405
40,274
45,511
47,671
48,530
48,53047,67145,51140,27450,40557,44951,21838,67444,9059,2677,3677,90140,34330,86526,57823,4415,73325,55119,38319,00736,26020,80720,68914,95112,93510,9776,2385,6016,8979,2256,7716,9648,2644,5979,9412,7202,2841,8431,5241,3869180001,174
   > Long-term Liabilities 
0
0
0
0
61,321
74,782
179
74,737
216
209
203
181
166
284
563
527
503
799
11,530
7,221
12,269
12,875
12,974
12,886
13,003
15,617
16,062
15,637
15,418
15,205
15,302
15,542
42,880
46,406
36,423
53,632
82,727
71,402
112,954
108,959
170,864
169,247
164,433
160,537
122,509
122,509160,537164,433169,247170,864108,959112,95471,40282,72753,63236,42346,40642,88015,54215,30215,20515,41815,63716,06215,61713,00312,88612,97412,87512,2697,22111,53079950352756328416618120320921674,73717974,78261,3210000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
196
141
85
244
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000244851411960000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-500
-10,300
-10,300
0
0
13,794
14,919
14,532
14,136
13,809
13,420
13,129
13,041
-10,872
-16,012
-4,540
22,765
17,453
63,999
60,235
58,064
42,308
51,754
48,508
45,693
45,69348,50851,75442,30858,06460,23563,99917,45322,765-4,540-16,012-10,87213,04113,12913,42013,80914,13614,53214,91913,79400-10,300-10,300-50000000000000000000000
       Warrants
0
0
0
0
0
0
0
149,144
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000149,1440000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
165
216
209
203
181
0
0
0
0
0
0
0
0
0
0
0
0
0
15,617
16,062
15,637
15,418
15,205
15,302
15,542
42,880
46,406
1,771
53,632
1,501
71,402
5,626
108,959
170,864
169,247
164,433
4,848
39,254
39,2544,848164,433169,247170,864108,9595,62671,4021,50153,6321,77146,40642,88015,54215,30215,20515,41815,63716,06215,61700000000000001812032092161650000000
> Total Stockholder Equity
2,984
0
0
0
-11,017
-14,704
56,223
-23,029
103,182
166,094
149,255
333,748
315,100
303,834
290,245
270,202
253,736
233,134
221,144
205,956
177,864
439,184
452,499
403,054
338,857
283,934
232,279
318,442
290,781
252,822
381,125
353,935
462,339
399,037
331,538
310,141
279,614
224,316
257,479
187,113
126,640
64,960
7,454
-50,838
-99,231
-99,231-50,8387,45464,960126,640187,113257,479224,316279,614310,141331,538399,037462,339353,935381,125252,822290,781318,442232,279283,934338,857403,054452,499439,184177,864205,956221,144233,134253,736270,202290,245303,834315,100333,748149,255166,094103,182-23,02956,223-14,704-11,0170002,984
   Common Stock
1
0
0
0
1
0
1
-19,909
2
2
2
3
3
3
3
3
3
3
3
3
3
4
5
5
5
5
5
5
6
6
7
8
8
8
8
9
9
9
9
9
10
10
10
10
11
111010101099999888876655555543333333333222-19,9091010001
   Retained Earnings Total Equity00-1,838,903-1,767,795-1,693,024-1,618,452-1,534,361-1,552,827-1,464,722-1,371,373-1,286,709-1,202,916-1,124,581-1,043,274-968,926-891,470-817,961-739,465-667,570-593,242-527,349-447,337-388,976-338,093-296,650-261,337-230,241-202,813-177,159-158,924-133,551-114,671-98,110-76,862-64,994-50,049-40,889-30,3620000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-3,823
-11
0
-11
-100
-18
-66
51
-518
51
193
35
-183
-152
-114
-88
-151
-524
-505
-449
-340
38
173
233
220
204
810
527
296
161
62
24
-368
-1,892
-2,618
-2,959
-2,067
-1,237
-933
-571
-204
-204-571-933-1,237-2,067-2,959-2,618-1,892-368246216129652781020422023317338-340-449-505-524-151-88-114-152-1833519351-51851-66-18-100-110-11-3,8230000
   Capital Surplus 
0
0
0
0
0
0
0
7,344
144,169
216,159
214,313
410,556
413,725
418,451
423,600
429,088
431,075
436,096
451,496
467,378
474,662
777,797
841,975
850,835
866,541
877,133
899,671
1,057,669
1,108,516
1,144,082
1,349,234
1,396,674
1,586,616
1,601,784
1,618,177
1,681,481
1,744,695
1,779,026
1,794,449
1,808,515
1,821,721
1,833,982
1,847,280
0
0
001,847,2801,833,9821,821,7211,808,5151,794,4491,779,0261,744,6951,681,4811,618,1771,601,7841,586,6161,396,6741,349,2341,144,0821,108,5161,057,669899,671877,133866,541850,835841,975777,797474,662467,378451,496436,096431,075429,088423,600418,451413,725410,556214,313216,159144,1697,3440000000
   Treasury Stock000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
1,865
5,239
84,477
7,344
144,169
216,159
214,313
410,556
413,725
418,451
423,600
429,088
431,075
436,096
451,496
467,378
474,662
777,797
841,975
850,835
866,541
877,133
899,671
1,057,669
1,108,516
1,144,082
1,349,234
1,396,674
1,586,616
1,601,784
1,618,177
1,681,481
1,744,695
1,779,026
1,794,449
1,808,515
1,821,721
1,833,982
1,847,280
1,858,423
1,870,112
1,870,1121,858,4231,847,2801,833,9821,821,7211,808,5151,794,4491,779,0261,744,6951,681,4811,618,1771,601,7841,586,6161,396,6741,349,2341,144,0821,108,5161,057,669899,671877,133866,541850,835841,975777,797474,662467,378451,496436,096431,075429,088423,600418,451413,725410,556214,313216,159144,1697,34484,4775,2391,8650000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue8,573
Cost of Revenue-8,886
Gross Profit-313-313
 
Operating Income (+$)
Gross Profit-313
Operating Expense-268,963
Operating Income-269,276-269,276
 
Operating Expense (+$)
Research Development219,166
Selling General Administrative50,908
Selling And Marketing Expenses1,111
Operating Expense268,963271,185
 
Net Interest Income (+$)
Interest Income4,797
Interest Expense-5,285
Other Finance Cost-1,432
Net Interest Income944
 
Pretax Income (+$)
Operating Income-269,276
Net Interest Income944
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-276,111-262,441
EBIT - interestExpense = -274,561
-276,111
-270,841
Interest Expense5,285
Earnings Before Interest and Taxes (EBIT)-269,276-270,826
Earnings Before Interest and Taxes (EBITDA)-264,447
 
After tax Income (+$)
Income Before Tax-276,111
Tax Provision-6
Net Income From Continuing Ops-290,248-276,117
Net Income-276,126
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses277,849
Total Other Income/Expenses Net-6,835-944
 

Technical Analysis of Atara Biotherapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Atara Biotherapeutics Inc. The general trend of Atara Biotherapeutics Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Atara Biotherapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Atara Biotherapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.8325 < 0.8896 < 0.9375.

The bearish price targets are: 0.5906 > 0.5686 > 0.4323.

Tweet this
Atara Biotherapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Atara Biotherapeutics Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Atara Biotherapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAtara Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Atara Biotherapeutics Inc. The current adx is .

Atara Biotherapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily Relative Strength Index (RSI) ChartAtara Biotherapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily Stochastic Oscillator ChartAtara Biotherapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily Commodity Channel Index (CCI) ChartAtara Biotherapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAtara Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily Williams %R ChartAtara Biotherapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily Average True Range (ATR) ChartAtara Biotherapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily On-Balance Volume (OBV) ChartAtara Biotherapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily Money Flow Index (MFI) ChartAtara Biotherapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Atara Biotherapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-30MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-08ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Atara Biotherapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Atara Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.690
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Atara Biotherapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Atara Biotherapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Atara Biotherapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Atara Biotherapeutics Inc

I send you an email if I find something interesting about Atara Biotherapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Atara Biotherapeutics Inc.

Receive notifications about Atara Biotherapeutics Inc in your mailbox!